Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isoleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 9/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL247127 | 1.00 | SLC7A5 (0.52) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL31703777 | 1.00 | SLC7A5 (0.52) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL16893956 | 1.00 | SLC7A5 (0.52) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL3000366 | 1.00 | SLC7A5 (0.52) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL6780686 | 1.00 | SLC7A5 (0.52) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL16893955 | 1.00 | SLC7A5 (0.52) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL1255582 | 0.97 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL20340795 | 0.97 | — | — | |
| Isoleucine SCHEMBL8868 | 0.97 | — | — | |
| Isoleucine SCHEMBL1255583 | 0.97 | SLC7A5 (0.55) | SLC7A5DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112409200-B | Preparation method and application of isoleucine chelate metal | 长沙兴嘉生物工程股份有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-112409200-A | Preparation method and application of isoleucine chelated metal | 长沙兴嘉生物工程股份有限公司 | 2021-02-26 | — | — | CN | claimed |
| US-10258579-B2 | Process for the preparation of polysaccharide nanoparticles | NANOVELOS SP. Z O.O. (PL) | 2019-04-16 | — | — | US | claimed |
| EP-3082778-B1 | STABLE LIQUID FILLED HARD CAPSULE COMPRISING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID | CAPSUGEL BELGIUM NV (BE) | 2019-04-03 | — | — | EP | claimed |
| US-20150197483-A1 | METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIHYDROCHLORIDE | WARSAW ORTHOPEDIC, INC. (US) | 2015-07-16 | — | — | US | claimed |
| CN-103951572-A | Separation and purification process for producing branched chain amino acid by using fermentation method | WUXI JINGHAI AMINO ACID CO LTD | 2014-07-30 | — | — | CN | claimed |
| US-6673942-B1 | PREFERENTIAL CRYSTALLIZATION, PHYSICAL SEPARATION | DEGUSSA AG (DE) | 2004-01-06 | — | — | US | claimed |
| EP-1254092-A1 | RESOLUTION OF DL-RACEMIC MIXTURES | Degussa AG (DE) | 2002-11-06 | — | — | EP | claimed |
| WO-2001058835-A1 | RESOLUTION OF DL-RACEMIC MIXTURES | DEGUSSA AG (DE) | 2001-08-16 | — | — | WO | claimed |
| US-5480574-A | 2-aminocarboxylic acid hydrochloride compositions for removal of hard-water deposits | SINGERMAN GARY M (US) | 1996-01-02 | — | — | US | claimed |
| JP-59062554-A | — | — | None | — | — | JP | disclosed |
| CN-119818525-A | Cytarabine amino acid ester composition and application thereof | 沈阳信达泰康医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119265261-A | Culture medium for producing tylosin through fermentation and preparation method thereof | 宁夏泰益欣生物科技股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024261477-A1 | COMBINATION OF TLR4 ANTAGONIST, ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE | YAQRIT LIMITED (GB) | 2024-12-26 | — | — | WO | disclosed |
| CN-112409200-B | Preparation method and application of isoleucine chelate metal | 长沙兴嘉生物工程股份有限公司 | 2023-06-20 | — | — | CN | disclosed |
| WO-1993006217-A1 | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES | GENENTECH, INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| EP-0241094-A1 | Process for the separation of L-leucine and L-isoleucine | PFW (NEDERLAND) B.V. (NL) | 1987-10-14 | — | — | EP | disclosed |
| JP-S5962554-A | PURIFICATION OF ISOLEUCINE HYDROCHLORIDE | TANABE SEIYAKU CO LTD | 1984-04-10 | — | — | JP | disclosed |
| US-4263450-A | PRECIPITATION AS HYDROCHLORIDE | SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) | 1981-04-21 | — | — | US | disclosed |
| US-3959075-A | CULTURING CORYNEFORM MUTANT | KYOWA HAKKO KOGYO CO., LTD. (JA) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197483-A1 | METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIHYDROCHLORIDE | ALKBH3, AADAT, ALKBH1 | DPP4 2619/4885SLC7A5 1032/4885DPP8 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.